Search results for " disease management"

showing 7 items of 27 documents

An Expert Opinion From the European Society of Hypertension–European Union Geriatric Medicine Society Working Group on the Management of Hypertension…

2016

Two years after the publication of the 2013 guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC),1 the ESH and the European Union Geriatric Medicine Society have created a common working group to examine the management of hypertensive subjects aged >80 years. The general term hypertension in the elderly is not sufficiently accurate because it mixes younger old patients (60–70 years) with the oldest old. Our group believes that the management of hypertension in individuals aged ≥80 years should be specifically addressed. Although arbitrary, this cutoff value identifies a population that is expanding …

MaleGerontologyBLOOD-PRESSUREL-ARGININE TRANSPORTFAT-FED RABBITS030204 cardiovascular system & hematologySeverity of Illness IndexSYMPATHETIC-NERVE ACTIVITY0302 clinical medicine80 and overPerindopril030212 general & internal medicineDisease management (health)Societies MedicalComputingMilieux_MISCELLANEOUSMETABOLIC SYNDROMEmedia_commonAged 80 and overGeriatricseducation.field_of_study[SDV.MHEP] Life Sciences [q-bio]/Human health and pathology[SDV.MHEP.GEG] Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontology[SDV.MHEP.GEG]Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontologyIndapamideDisease ManagementPrognosis[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system3. Good healthAntihypertensive AgentTreatment OutcomeHypertensionPractice Guidelines as TopicFemaleSurvival AnalysiHumanmedicine.drugANGIOTENSIN-CONVERTING ENZYMEmedicine.medical_specialtyPrognosiFrail ElderlyeducationPopulationRisk Assessment03 medical and health sciences[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemMedicalInternal MedicinemedicineHumansmedia_common.cataloged_instanceEuropean UnionNITRIC-OXIDE SYNTHASEEuropean unioneducationREDUCES OXIDATIVE STRESSExpert TestimonyGeriatric AssessmentAntihypertensive AgentsAgedAged; Aged 80 and over; Antihypertensive Agents; Blood Pressure Determination; Disease Management; European Union; Expert Testimony; Female; Frail Elderly; Geriatric Assessment; Geriatrics; Humans; Hypertension; Male; Prognosis; Risk Assessment; Severity of Illness Index; Societies Medical; Survival Analysis; Treatment Outcome; Practice Guidelines as Topic; Internal Medicinebusiness.industryBlood Pressure DeterminationSurvival AnalysisBlood pressureOBESITY-INDUCED HYPERTENSIONGeriatrics3121 General medicine internal medicine and other clinical medicineENDOTHELIAL DYSFUNCTIONLife expectancySocietiesbusinessGeriatric[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyHypertension
researchProduct

2017 WSES guidelines for the management of iatrogenic colonoscopy perforation

2017

Abstract Iatrogenic colonoscopy perforation (ICP) is a severe complication that can occur during both diagnostic and therapeutic procedures. Although 45–60% of ICPs are diagnosed by the endoscopist while performing the colonoscopy, many ICPs are not immediately recognized but are instead suspected on the basis of clinical signs and symptoms that occur after the endoscopic procedure. There are three main therapeutic options for ICPs: endoscopic repair, conservative therapy, and surgery. The therapeutic approach must vary based on the setting of the diagnosis (intra- or post-colonoscopy), the type of ICP, the characteristics and general status of the patient, the operator’s level of experienc…

MaleIatrogenic DiseaseColonoscopyReviewIatrogenic colonoscopy perforation0302 clinical medicine80 and overOpen abdomenAged 80 and overintegumentary systemmedicine.diagnostic_testmusculoskeletal neural and ocular physiologylcsh:Medical emergencies. Critical care. Intensive care. First aidDisease ManagementIatrogenic colonoscopy perforation Colonoscopy Gastrointestinal endoscopy Emergency surgery Laparoscopy Antibiotic therapy Intra-abdominal infection Open abdomenColonoscopyMiddle Agedhumanities030220 oncology & carcinogenesisEmergency surgeryEmergency MedicineFemale030211 gastroenterology & hepatologymedicine.medical_specialtyColonPerforation (oil well)lcsh:SurgeryGuidelines as TopicSigns and symptomsGeneral status03 medical and health sciencesTherapeutic approachIntra-abdominal infectionEmergency surgerymedicineHumansGastrointestinal endoscopyIntensive care medicineAgedbusiness.industrylcsh:RD1-811lcsh:RC86-88.9Antibiotic therapyEndoscopic Procedurenervous system diseasesSettore MED/18 - Chirurgia GeneraleIntestinal PerforationAntibiotic therapy; Colonoscopy; Emergency surgery; Gastrointestinal endoscopy; Iatrogenic colonoscopy perforation; Intra-abdominal infection; Laparoscopy; Open abdomen; Aged; Aged 80 and over; Colon; Colonoscopy; Disease Management; Female; Humans; Intestinal Perforation; Male; Middle Aged; Guidelines as Topic; Iatrogenic DiseaseAntibiotic therapy; Colonoscopy; Emergency surgery; Gastrointestinal endoscopy; Iatrogenic colonoscopy perforation; Intra-abdominal infection; Laparoscopy; Open abdomen;LaparoscopySurgerySurgical devicebusiness
researchProduct

Ketogenic diet for infants with epilepsy: A literature review.

2020

Abstract The ketogenic diet (KD) is an established, nonpharmacological treatment for drug-resistant epilepsy (DRE). Actually, KD and its variants have been shown to be elective and resolute for patients with glucose transporter type 1 (GLUT1) deficiency. The aim of this review was to study the use of KD and its variants in infancy, including the neonatal age, and demonstrate the safety and efficacy of this treatment in patients with the age of 0–23 months affected by DRE already subjected to pharmacological approach attempts. A literature search was conducted using PubMed as the medical database source. We used the age limit of 0–23 months, and we considered only articles published between …

MalePediatricsmedicine.medical_specialtyDrug Resistant EpilepsyKetogenicmedicine.medical_treatmentDrug-resistant epilepsyDrug-resistant epilepsy Epilepsy Glucose transporter type 1 deficiency Infant Ketogenic diet Diet Ketogenic Disease Management Drug Resistant Epilepsy Epilepsy Female Glucose Transporter Type 1 Humans Infant. Infant Newborn. Male Seizures Treatment OutcomeNeonatal ageNewborn. MaleAge limitlaw.invention03 medical and health sciencesBehavioral NeuroscienceEpilepsy0302 clinical medicineRandomized controlled triallawSeizuresmedicineGlucose transporter type 1 deficiencyHumans030212 general & internal medicineProspective cohort studyGlucose Transporter Type 1Epilepsybusiness.industryInfant NewbornDisease ManagementInfantRetrospective cohort studyKetogenic dietInfant. InfantDrug Resistant Epilepsymedicine.diseaseDietTreatment OutcomeNeurologyFemaleNeurology (clinical)businessDiet Ketogenic030217 neurology & neurosurgeryKetogenic dietEpilepsybehavior : EB
researchProduct

Years of life that could be saved from prevention of hepatocellular carcinoma

2016

Summary Background Hepatocellular carcinoma (HCC) causes premature death and loss of life expectancy worldwide. Its primary and secondary prevention can result in a significant number of years of life saved. Aim To assess how many years of life are lost after HCC diagnosis. Methods Data from 5346 patients with first HCC diagnosis were used to estimate lifespan and number of years of life lost after tumour onset, using a semi-parametric extrapolation having as reference an age-, sex- and year-of-onset-matched population derived from national life tables. Results Between 1986 and 2014, HCC lead to an average of 11.5 years-of-life lost for each patient. The youngest age-quartile group (18–61 y…

RegistrieMalePediatricsDatabases FactualHepatocellular carcinoma0302 clinical medicineprevention80 and overSecondary PreventionPharmacology (medical)Prospective StudiesRegistriesYoung adultProspective cohort studySecondary preventionAged 80 and overeducation.field_of_studyLiver NeoplasmsGastroenterologyDisease ManagementMiddle AgedPrimary PreventiondiagnosiItalyLiver Neoplasm030220 oncology & carcinogenesisHepatocellular carcinoma030211 gastroenterology & hepatologyFemaleHumanAdultmedicine.medical_specialtyCarcinoma HepatocellularAdolescentPopulationlife expentancyMilan criteria03 medical and health sciencesDatabasesYoung AdultLife ExpectancymedicineHumansAdolescent; Adult; Aged; Aged 80 and over; Carcinoma Hepatocellular; Databases Factual; Disease Management; Female; Humans; Italy; Life Expectancy; Liver Neoplasms; Male; Middle Aged; Primary Prevention; Prospective Studies; Registries; Secondary Prevention; Young Adult; Pharmacology (medical)educationFactualAgedHepatologybusiness.industryCarcinomaSettore MED/09 - MEDICINA INTERNAHepatocellularmedicine.diseaseSurgeryProspective StudieYears of potential life lostLife expectancybusiness
researchProduct

The calm before the storm: a report from the International Liver Cancer Association Congress 2015 – part 1

2016

International Liver Cancer Association Congress 2015, Paris, France, 4–6 September 2015 Since its creation 9 years ago, in 2007, the International Liver Cancer Association has focused on the multidisciplinary approach to liver cancer due to advances in hepatology science and care worldwide. In its 2015 annual conference, held on 4–6 September in Paris, France, the most recent progresses in the basic biology, management and treatment of liver cancer have been presented. This report, divided into two parts, introduces and critically reviews some of the most intriguing topics discussed at the meeting.

SorafenibCancer Researchmedicine.medical_specialtysurvivalliver cancer03 medical and health sciences0302 clinical medicineInternal medicinestaging systemmedicineHumansHCCDisease management (health)Staging systembusiness.industryCarcinomaLiver NeoplasmsDisease ManagementHCC; immunotherapy; liver cancer; prognosis; sorafenib; staging system; survival; trial design; Carcinoma Hepatocellular; Disease Management; Humans; Liver Neoplasms; Oncology; Cancer ResearchHepatocellularGeneral MedicineHepatologymedicine.diseaseOncology030220 oncology & carcinogenesisFamily medicinetrial designsorafenib030211 gastroenterology & hepatologyimmunotherapyprognosisLiver cancerbusinessmedicine.drugFuture Oncology
researchProduct

A recommended practical approach to the management of anthracycline-based chemotherapy cardiotoxicity: an opinion paper of the working group on drug …

2016

Anthracyclines are the mainstay of treatment of a variety of haematological malignancies and solid tumours. Unfortunately, the clinical use of these drugs is limited by cumulative, dose-related cardiotoxicity which may ultimately lead to a severe and irreversible form of cardiomyopathy. Thus, there is an increasing need for close cooperation among cardiologists, oncologists and haemato-oncologists. As anthracyclines save lives, the logical goal of this cooperation, besides preventing or mitigating cardiotoxicity, is to promote an acceptable balance between the potential cardiac side effects and the vital benefit of anticancer treatment. This manuscript, which is specifically addressed to th…

cardio-oncologymedicine.medical_treatmentCardiomyopathyheart failure030204 cardiovascular system & hematologyanthracyclines; cardio-oncology; cardiology consult; cardiotoxicity; heart failure; Anthracyclines; Antibiotics Antineoplastic; Cardiology; Cardiomyopathies; Cardiotoxicity; Humans; Italy; Neoplasms; Practice Guidelines as Topic; Societies Medical; Disease Managementanthracyclines; cardiotoxicity; heart failurecardiology consult0302 clinical medicineCardiologistsAntibioticsNeoplasmsDisease management (health)Societies Medicalmedia_commonanthracyclinesAntibiotics AntineoplasticDisease ManagementGeneral MedicineAntineoplasticItalyCardiovascular Diseases030220 oncology & carcinogenesisSupplement SubmissionPractice Guidelines as TopicCardiologyCardiomyopathiesRisk assessmentCardiology and Cardiovascular MedicineDrugmedicine.medical_specialtyAnthracyclinemedia_common.quotation_subjectCardiologycardiotoxicityanthracyclines; cardio-oncology; cardiology consult; cardiotoxicity; heart failure; Cardiology and Cardiovascular MedicineAntineoplastic AgentsanthracyclineRisk Assessment03 medical and health sciencesMedicalInternal medicinemedicineHumansIntensive care medicineCardiotoxicityChemotherapybusiness.industrymedicine.diseaseHeart failureSocietiesbusinessJournal of cardiovascular medicine (Hagerstown, Md.)
researchProduct

Asthma-Related Knowledge and Practices among Mothers of Asthmatic Children: A Latent Class Analysis

2022

Mothers’ knowledge about childhood asthma influences management practices and disease control, but validating knowledge/practice questionnaires is difficult due to the lack of a gold standard. We hypothesized that Latent Class Analysis (LCA) could help identify underlying mother profiles with similar knowledge/practices. A total of 438 mothers of asthmatic children answered a knowledge/practice questionnaire. Using answers to the knowledge/practice questionnaire as manifest variables, LCA identified two classes: Class 1, “poor knowledge” (33%); Class 2, “good knowledge” (67%). Classification accuracy was 0.96. Mothers in Class 2 were more likely to be aware of …

knowledgeHealth Toxicology and Mutagenesispractices.Public Health Environmental and Occupational Healthlatent profilesasthmaasthma; children; disease management; knowledge; latent profiles; mothers; practices.mothersPracticeschildrendisease managementLatent Class AnalysisSurveys and QuestionnairesEducational StatusHumansFemaleasthma; children; knowledge; latent profiles; disease management; mothers; practicesChildInternational Journal of Environmental Research and Public Health
researchProduct